Prof. Karim Fizazi is a medical oncologist and Professor of Oncology at the University of Paris-Saclay, France. Appointed General Director of Centre Oscar Lambret in Lille from March 2026, he previously led the Genitourinary Oncology Group and the International Academic Network at Gustave Roussy Cancer Campus for many years. A globally recognised expert in prostate and testicular cancers, he has chaired a series of practice-changing international trials including LATITUDE (abiraterone in metastatic prostate cancer), ARAMIS (darolutamide in non-metastatic CRPC), TRITON-3, and the PEACE-1 and PEACE-2 Phase III trials under the PEACE consortium he founded in 2013. He is President of the French Genitourinary Tumour Group (GETUG) and was elected ESMO Director of Public Policy in the 2025 ESMO elections. He is Associate Editor of the European Journal of Cancer and has authored more than 500 scientific publications.